Pall Corporation Signs Long-Term Agreement with American Red Cross to Provide Blood Collection Systems

Strategic Insights -

Pall Corporation, a global leader in filtration, separations, and purification, announced a new long-term agreement with the American Red Cross (ARC) to provide blood collection systems incorporating Pall's proprietary filtration and venting technology. The agreement will support the ARC's mission to provide blood and blood products to patients in need, with a focus on improving patient outcomes and controlling healthcare costs. The Leukotrap family of filter systems, developed by Pall in the late 1980s, will play a pivotal role in this effort.

Key Takeaways:

  • The agreement between Pall Corporation and the American Red Cross (ARC) is a major contract for Pall's Leukotrap family of filter systems, considering the ARC's position as one of the largest suppliers of blood and blood products in the U.S.
  • Approximately 14 million units of blood are collected in the United States annually, with the ARC collecting about 6 million units annually.
  • Leukoreduction, the removal of contaminating white blood cells from blood products, is a critical aspect of improving patient outcomes and controlling healthcare costs, with Pall's filter systems serving as the leading provider of these systems worldwide.
  • Pall Corporation offers a broad portfolio of filtration systems that remove leukocytes from red cells, plasma, and platelets, providing customers with maximum flexibility in the manufacturing of life-saving blood products.
  • The company's total revenues for fiscal 2004 were $1.8 billion, with a global presence and extensive operations throughout the world.
  • Pall's business is organized around two broad markets: Life Sciences and Industrial, with a focus on providing leading-edge products to meet the demanding needs of customers in various sectors.

Statistics:

  • Approximately 14 million units of blood are collected in the United States annually.
  • The American Red Cross collects about 6 million units of blood annually, with the potential for growth through Pall's Leukotrap technology.
  • Pall Corporation's total revenues for fiscal 2004 were $1.8 billion.
  • Pall's Leukotrap family of filter systems has been developed since the late 1980s, establishing the company as the leading provider of leukoreduction filters worldwide.

Sources:

  • "Pall Corporation Signs New Long-Term Agreement with American Red Cross." Business Wire, July 25, 2005.
  • "About Pall Corporation." Pall Corporation, http://www.pall.com.